Infectious Diseases Catch-up (CID + OFID) 2026-06-20

A one-time catch-up over five weeks of online-first CID content. Headliners: FARTHEST makes moxifloxacin clearly superior to azithromycin for M. genitalium; a clean fosfomycin oral step-down for ESBL cUTI proves non-inferior to IV; ACTIV-6 is a rigorous negative on metformin for long COVID; STOP-Vanc shows an MRSA-nares swab adds nothing on top of good stewardship; plus real-world lenacapavir PrEP, two early-phase agents (VH-184 INSTI, S-337395 RSV polymerase inhibitor), a HAP/VAP newer-vs-generic meta-analysis, the BioFire pneumonia panel in the VA, and the methods-heavy ADVANCE-ID supplement. RCTs are in PICO; high-yield non-RCT work gets a structured key-takeaway; the long tail runs as one-liners below.

Subscription · academic.oup.com/cid

Clinical Infectious Diseases (CID)

New since the May 15 issue · May 16–Jun 20, 2026 · 31 articles

Randomized Controlled Trials

Bacterial / STIRCT · superiorityHigh yield · carded

FARTHEST — Moxifloxacin vs Azithromycin for Mycoplasma genitalium

In adults with PCR-detected M. genitalium and no resistance testing, is moxifloxacin superior to azithromycin for microbiological cure?

Population: 358 adults, single-center (Milan); open-label superiority RCT, 1:1; no macrolide-resistance testing.
Intervention: Moxifloxacin 400 mg daily × 10 days.
Comparison: Azithromycin 500 mg daily × 6 days (extended).
Outcome: Microbiological cure 87.0% vs 61.2% (ITT); difference 25.8% (95% CI 16.5–35.2); per-protocol 95.5% vs 67.3%. Superiority confirmed.

Clinical takeaway. Moxifloxacin clearly beats even an extended azithromycin course where resistance assays are unavailable, reflecting rising macrolide resistance. What this changes: supports moxifloxacin first-line when resistance testing isn't available; reinforces moving away from empiric azithromycin monotherapy.

PDF: moxifloxacin-vs-azithromycin-m-genitalium-farthest-rct.pdf

Stewardship / ResistanceRCT · non-inferiorityHigh yield · carded

Fosfomycin Oral Step-Down vs Continued IV β-Lactams for ESBL Complicated UTI

In ESBL-Enterobacterales cUTI improving on IV therapy, is oral fosfomycin step-down non-inferior to continued IV β-lactams?

Population: 299 adults, 4 Korean tertiary hospitals; ESBL-Enterobacterales cUTI improved after 3–7 d IV; open-label NI RCT.
Intervention: Oral fosfomycin trometamol 3 g daily (152).
Comparison: Continued IV carbapenem or β-lactam/β-lactamase inhibitor (147).
Outcome: Clinical cure 92.8% vs 95.2%; risk difference −2.47% (95% CI −7.84 to +2.89), within the 15% margin → non-inferiority confirmed.

Clinical takeaway. A carbapenem-sparing oral exit that enables earlier discharge for ESBL cUTI. Open-label, single-country — reserve for improving patients with susceptible isolates. What this changes: extends oral step-down to a resistant pathogen.

PDF: fosfomycin-oral-transition-vs-iv-beta-lactams-esbl-cuti-rct.pdf

Diagnostics / StewardshipRCT · pragmaticHigh yield · carded

STOP-Vanc — MRSA-Nares Swab to Optimize Empiric Vancomycin in ICU Pneumonia

In ICU adults with suspected pneumonia, does adding MRSA-nares PCR reduce empiric vancomycin exposure?

Population: 277 ICU adults with suspected community-acquired pneumonia; pragmatic single-center non-blinded RCT.
Intervention: Usual care plus MRSA-nares PCR (NPV 98.9%).
Comparison: Usual care without the swab.
Outcome: Vancomycin-free hours alive in 7 d 109.7 vs 105.7; adjusted difference 4 h (95% CI −9.5 to 18.2; P=.458); no mortality difference (26% vs 35%).

Clinical takeaway. Despite a 98.9% NPV the swab didn't cut vancomycin — pharmacist-led stewardship already stopped it early (~40 h in controls). What this changes: tempers reflexive MRSA-nares swabbing as a standalone vancomycin-sparing tool.

PDF: swab-testing-optimize-empiric-vancomycin-pneumonia-stop-vanc-rct.pdf

Viral / COVIDRCT · platformHigh yield · carded

ACTIV-6 — Metformin for Prevention of Long COVID at 6 Months

In low-risk outpatients with acute COVID-19, does a 14-day metformin course reduce long COVID (PASC) at day 180?

Population: 2983 outpatient adults ≥30 y (mITT 1439/1544); quadruple-blinded placebo-controlled ACTIV-6 platform RCT.
Intervention: Metformin × 14 days.
Comparison: Placebo.
Outcome: PASC at day 180 RR 0.79 (95% CrI 0.474–1.230); posterior probability of efficacy 0.83, below the 0.975 threshold → did NOT meet efficacy. (Unadjusted day-120 RR 0.65.)

Clinical takeaway. A rigorous negative trial — metformin did not prevent long COVID in low-risk outpatients. What this changes: weighs against the earlier COVID-OUT long-COVID secondary signal; not actionable.

PDF: metformin-covid-19-symptoms-6-months-activ-6-rct.pdf

VaccinesPhase 3 · RCT (NI)High yield · carded

Co-administration of AS01_E-Adjuvanted RSVPreF3 with a COVID-19 mRNA Vaccine in Adults ≥50

In adults ≥50, does co-administering RSVPreF3 with an XBB.1.5 COVID-19 mRNA vaccine preserve immune responses vs giving them ~1 month apart?

Population833 adults ≥50 (Co-Ad 417 / sequential 416); open-label phase 3 non-inferiority RCT. Intervention / ComparisonSame-visit co-administration vs sequential (~1 month apart); NI margin upper 95% CI of GMT ratio ≤1.50. OutcomeNI met for RSV-A (1.12) and RSV-B (1.08); marginally missed for SARS-CoV-2 XBB.1.5 (1.31; 95% CI 1.13–1.51). Reactogenicity mostly mild–moderate.

Clinical takeaway. RSV responses are fully preserved; the borderline SARS-CoV-2 miss is judged not clinically relevant. What this changes: supports same-visit RSV + COVID vaccination to improve uptake in older adults.

PDF: rsv-pref-covid-mrna-coadministration-phase3-rct.pdf

HIV / New agentPhase 2a · RCTLower yield · early phase

VH-184 (VH4524184) — Third-Generation INSTI, Phase 2a Proof-of-Concept

In ART-naive adults with HIV-1, does short-course VH-184 monotherapy reduce viral load with a clean resistance profile?

Population / Design: 22 ART-naive adults (VH-184 n=19 / placebo n=3); randomized, double-blind phase 2a monotherapy (Days 1/4/7, then SOC ART).
Outcome: Mean max HIV-1 RNA reduction −1.17 / −2.15 / −2.31 log₁₀ (10/50/300 mg); no SAEs/deaths; no resistance through Day 10.

Clinical takeaway. Dose-dependent potency with an enhanced resistance barrier supports VH-184 as a candidate core INSTI. What this changes: pipeline only — phase 2a, surrogate.

Viral / New agentPhase 2a · challenge RCTLower yield · early phase

S-337395 — RSV L-Protein Inhibitor, Phase 2a Human Challenge

In a controlled RSV human-challenge model, does the oral L-protein inhibitor S-337395 reduce viral load vs placebo?

Population / Design: 114 healthy adults 18–55 (60 infected); RSV-A challenge; randomized, double-blind placebo-controlled phase 2a.
Outcome: Viral-load AUC reduced −64.9% (30 mg) and −88.9% (300 mg) vs placebo (both P<.05); symptom-score AUC −78.2% (300 mg). Well tolerated.

Clinical takeaway. Strong dose-dependent antiviral signal for a novel oral RSV polymerase inhibitor — a class with real potential where RSV still lacks good treatment. What this changes: pipeline only — surrogate, healthy volunteers; needs field trials.

Guideline / Guidance Updates

No formal IDSA/society clinical guideline posted this window. The ADVANCE-ID supplement (below) carries antibiotic-trial methodology and AMR-policy guidance rather than clinical practice recommendations.

Major Studies & New Antimicrobials

HIV / PreventionReal-world cohortHigh yield · carded

Real-World Implementation of Lenacapavir for HIV PrEP — US Multicenter Cohort

•What changed / key figure: 501 LEN PrEP initiators, 17 programs. Prior authorization added an 11.6-day delay (95% CI 6.2–17.0). All early nonpersistence occurred with abdominal injections (5.3% vs 0% thigh); ISR requiring contact 14.4%. •Fellow-level implication: LEN PrEP is deliverable, but access friction is real and injection-site matters — prefer the thigh to reduce ISRs and early discontinuation.

PDF: real-world-lenacapavir-hiv-prep-multicenter-us-cohort.pdf

Stewardship / AMRMeta-analysis · 8 RCTsHigh yield · carded

Newer vs Generic Antibiotics for HAP/VAP — Meta-Analysis of RCTs (ADVANCE-ID)

•What changed / key figure: 8 RCTs (2881 patients). No difference in 28-day mortality (RR 0.97; 95% CI 0.72–1.30) or clinical/microbiological response, but less nephrotoxicity vs colistin (RR 0.30) and better eradication of carbapenem-resistant GNB (RR 1.50; 95% CI 1.18–1.90). •Fellow-level implication: newer β-lactam/BLI agents match generics on survival but win on safety and CRO eradication — favor them over polymyxin-based regimens for carbapenem-resistant GNB pneumonia.

PDF: newer-vs-generic-antibiotics-hap-vap-meta-analysis.pdf

Diagnostics / StewardshipDifference-in-differencesHigh yield · carded

BioFire FilmArray Pneumonia Panel in the VA — Difference-in-Differences

•What changed / key figure: 36 VHA hospitals, 11,746 ICU pneumonia patients. PN panel → more early de-escalation (aRR 1.14; 95% CI 1.04–1.26) and lower ICU mortality in culture-positive patients (aRR 0.70; 95% CI 0.50–0.97); benefit greatest with stronger ASP. •Fellow-level implication: rapid syndromic PN panels optimize antibiotics only when coupled to an active stewardship program — the diagnostic is only as good as the team acting on it.

PDF: biofire-filmarray-pneumonia-panel-clinical-impact-va.pdf

TBTarget trial emulationHigh yield · carded

Linezolid Management for Neuropathy in MDR/RR-TB — endTB Target Trial Emulation

•What changed / key figure: 303 patients, 12 countries. Treatment success 85.2% (no change) vs 84.7% (immediate change) vs 78.9% (deferred); success ratio 0.99 (95% CI 0.83–1.11) immediate vs no change. •Fellow-level implication: reducing or interrupting linezolid 600 mg for non-severe neuropathy does NOT meaningfully reduce cure — adjust for tolerability without sacrificing MDR-TB efficacy.

PDF: linezolid-neuropathy-mdr-tb-target-trial.pdf

Bacterial / AMRProspective surveillanceHigh yield

ACORN2 — Mortality & LOS of Community-Acquired E. coli & S. aureus BSI in 9 LMICs

•What changed / key figure: in-hospital mortality 8.4% (culture-neg) / 20.1% (E. coli) / 13.1% (S. aureus); 3GC-resistance and MRSA were NOT associated with higher adjusted mortality; excess LOS for resistant vs susceptible just 1–2 days (CIs spanning 0). •Fellow-level implication: in these LMIC settings the organism and timely effective therapy drove outcomes more than the resistance label — attributable-AMR mortality is setting-dependent.

PDF: mortality-los-ecoli-saureus-bsi-9-lmics-acorn2.pdf

Vaccines / RabiesComparative immunogenicityHigh yield · carded

Resist-3 — 3- vs 4-Session Intradermal Rabies PEP, Long-Term Immunogenicity

•What changed / key figure: 181 people boosted 2/5/10 years after 3- or 4-session intradermal PEP. All reached protective RVNA ≥0.5 IU/mL by day 7 after a booster in both groups; day-0/day-7 GMTs did not differ significantly. •Fellow-level implication: the abridged 3-session intradermal PEP gives durable priming and a robust anamnestic response out to 10 years — supports it where it cuts cost/visits and improves completion.

PDF: intradermal-rabies-pep-3-vs-4-session-resist-3.pdf

Viral / InfluenzaSurveillance (FluSurv-NET)High yield · carded

Bacterial Co-detections by Blood Culture in Hospitalized Influenza — FluSurv-NET

•What changed / key figure: 14,316 influenza hospitalizations; 5.2% had a bacterial co-detection. Mortality rose stepwise 1.5% → 3.3% → 9.4% → 14.5% (>1 co-detection); S. aureus (22.1% of positives) and S. pneumoniae each ~22.4% mortality. •Fellow-level implication: bacteremic co-infection marks severe influenza, with S. aureus the dominant co-pathogen — keep MRSA/MSSA coverage in mind for the sick post-influenza patient and push vaccination.

PDF: bacterial-co-detections-blood-culture-hospitalized-influenza-flusurv-net.pdf

More notable — summary-only

•Early antibiotic stop in pediatric haplo-HCT febrile neutropenia (Transplant ID): pre/post quasi-experiment — days of therapy −8 (P<.01), no excess BSI/ICU/death; supports stopping empiric antibiotics in stable culture-negative FN. •COVID vaccination & breakthrough-severity attenuation (Vaccines): meta-analysis — relative VE for hospitalization vs symptomatic infection 51% (95% CI 39–60); platform-independent, no significant waning. •Valve strands in suspected endocarditis (Bacterial): of 305 episodes only 33% were IE; distinguish Lambl's excrescences from vegetations by expert/multidisciplinary review to avoid overtreatment. •FDG-PET/CT for paracoccidioidomycosis staging (Mycology): PET/CT found >2× the lesions of conventional staging (150 vs 62) and upstaged 70.6%→91.2% as severe.

ADVANCE-ID supplement & agents to watch

•ADVANCE-ID network — ID trials network across 20 Asian countries (>100 hospitals, >12,000 enrolled) targeting serious AMR infections in the "AMR hot zone." •Antibiotic-trial challenges & solutions + superiority-design considerations — why antibiotic RCT evidence is thin and how platform/adaptive designs help. •Consent in severe-infection RCTs (112 RCTs) & global MDR-GNB management survey (1320 respondents, 76 countries) & access barriers to newer antibiotics in Asia. •Agents to watch: VH-184 (3rd-gen INSTI) and S-337395 (oral RSV L-protein inhibitor) — see the RCT cards above.

Also new this week (screened in, lower yield — no card): HCC surveillance adherence in PWH/HBV (only 28% guideline-adherent; ciag341); Safety of 3HP at conception/first trimester in WLHIV (WHIP3TB) (no excess adverse pregnancy outcomes, RR 1.02; ciag315); Multidimensional poverty & TB contact tracing (Kharituwe) (urban poverty lowered tracing initiation, aPR 0.903; ciag321); Weight-tiered cefazolin prophylaxis in obese colorectal surgery (PK/CT body-composition; ciag383); Phases of C. difficile infection in the US 1935–present (viewpoint, now a deceleration phase; ciag363); Medical cannabis & risk for infections (clinician guide; ciag343); Disseminated gonococcal infection in MSM (Correspondence; ciag359). Plus the ADVANCE-ID review of the past/present of antibiotic trials (ciag017) screened into the supplement box above.

Open Access · academic.oup.com/ofid + PMC

Open Forum Infectious Diseases (OFID)

Catch-up backfill · 92 articles archived (online Feb–Jun 2026) · 23 featured below; full set in the OFID Archive

Antimicrobial Stewardship & Resistance

Review / network meta-analysis · OFID · abstract-only

β-Lactam + Azithromycin vs Doxycycline vs Fluoroquinolones for hospitalized CAP

20 studies (6 RCTs). β-lactam + doxycycline ≈ β-lactam + azithromycin for mortality, ICU/ventilation, and safety (incl. C. difficile, QT). Fellow takeaway: doxycycline is a defensible atypical partner where macrolide resistance/QT/C. diff are concerns — supports moving off reflexive azithromycin.

PDF: beta-lactam-plus-azithromycin-or-doxycycline-vs-fluoroquinolones.pdf

Retrospective cohort · OFID · abstract-only

Oral step-down vs complete IV for uncomplicated Gram-negative bacteremia

9,164 adults. 90-day mortality 1.0% vs 1.4% (NS); readmission & recurrence favored oral step-down; among oral, fluoroquinolones beat β-lactams (recurrence 1.6% vs 3.2%). Channeling bias likely. Fellow takeaway: reinforces oral step-down for improving patients, FQ preferred where susceptible.

PDF: the-use-of-step-down-oral-antibiotic-therapy.pdf

Cohort · OFID · abstract-only

Linezolid TDM to enable prolonged OPAT courses

162 adults on linezolid ≥3 wks (mostly bone/joint). Early d/c for thrombocytopenia 14% (TDM) vs 31% (control); aOR 0.07. Fellow takeaway: trough-guided TDM markedly cuts treatment-limiting thrombocytopenia on the prolonged linezolid courses fellows run for osteoarticular infection.

PDF: clinical-impact-of-linezolid-therapeutic-drug-monitoring-on.pdf

Cohort · OFID · abstract-only

Daptomycin OPAT — lab-monitoring intensity

Only 6.6 OPAT adverse events per 1,000 weekly lab sets. Fellow takeaway: supports less-intensive (not strictly weekly) CPK/CBC monitoring for stable daptomycin OPAT patients.

PDF: serious-adverse-events-and-laboratory-monitoring-regimens-for.pdf

Also archived: RESPIRE resistant-CAP risk score (ofag319); β-lactam TDM in OPAT (ofag299); long-term suppression in prosthetic vascular graft infection (ofag327); MRSA impact on S. aureus bacteremia outcomes (ofag354); Japan stewardship-policy time-series (ofag312); dental stewardship (ofag287); 16S in ortho infections (ofag262); neonatal-bacteremia resistance epidemiology (ofag246).

Bacterial Infections

PK study · OFID · abstract-only

Oral amoxicillin PK for syphilis in pregnancy

Pregnancy lowers exposure (clearance up); simulation shows 750 mg q8h maintains %fT>MIC, q12h underperforms. Fellow takeaway: if using oral amoxicillin as a penicillin-allergy/shortage option for syphilis in pregnancy, dose q8h — small PK study, needs efficacy trials.

PDF: pharmacokinetics-of-oral-amoxicillin-for-the-treatment-of.pdf

Case series · OFID · abstract-only

Mold (Scedosporium / Lomentospora) endocarditis — S.O.S. cohort

30 cases; trauma/SOT/malignancy hosts; septic emboli 93% (CNS 68%), cultures negative 27%; mortality 71–88%, 100% with CNS emboli. Fellow takeaway: consider invasive mold endocarditis in embolic disease in trauma/transplant hosts; early surgery + mold-active antifungals, outcomes poor. (Archive title mislabels as Gemella/Abiotrophia — verify in PDF.)

PDF: endocarditis-due-to-gemella-spp-and-abiotrophia-case.pdf

Cohort · OFID · abstract-only

MOUD initiation in injection-drug-use–associated endocarditis

218 IDU-IE patients; MOUD associated with reduced 30-day post-discharge mortality. Fellow takeaway: inpatient MOUD initiation is part of IE care for PWID — integrate into the endocarditis pathway.

PDF: the-impact-of-moud-initiation-in-patients-with.pdf

Also archived: BACT-URIE score for IE in enterococcal bacteremia (ofag259); chronic melioidosis NT Australia 1989–2023 (ofag294); post-flood leptospirosis outbreak, Greece (ofag301); spotted fever vs scrub typhus (ofag264); imported malaria, NYC (ofag293); ICU vs non-ICU anaplasmosis (ofag313); IE quality-of-life, DERIVE (ofag238); enterococcal-IE "volume" viewpoint (ofag199); rectal STI symptoms in MSM (ofag276); spine-infection implant retention (ofag267); FQ/co-trimoxazole UTI safety in older men (ofag271); Switzerland meningitis/encephalitis trends (ofag350); placental pathogens (ofag229); pediatric diarrhea pathogen kinetics (ofag309); high-altitude malaria Ethiopia (ofag247); female-vs-male bacteremia (ofag260).

HIV

RCT (240-wk) · OFID · abstract-only

ODYSSEY — Dolutegravir vs SOC in children, 240-week

792 children. Treatment failure 19% (DTG) vs 34% (SOC), diff −15% (95% CI −21 to −9); safety similar. What this changes: long-term durability cements DTG as the pediatric anchor (per WHO), superiority sustained to ~4.6 yrs.

PDF: dolutegravir-as-first-or-second-line-treatment-for.pdf

RCT post hoc / pooled / survey · OFID · abstract-only

Three practice-relevant HIV studies

Doravirine viral blips W192: blips 11–12% (≈ comparators); a blip flags higher rebound risk (HR 3.79) — monitor, don't reflexively switch.
B/F/TAF renal outcomes: pooled 1,069 with mild-moderate CKD — renal function stable to 240 wks; reassuring TDF-sparing option.
LA-CAB/RPV US implementation: wide uptake but structural/financial barriers and guidance gaps for youth/obesity.

Also archived (13): transmitted-resistance trends Spain (ofag296); low-level rebound 2- vs 3-drug, ICONA (ofag250); doxy-PEP engagement/STI screening (ofag251); steatotic liver disease in PWH (ofag325); histoplasmosis in advanced HIV, Uganda (ofag302); epigenetic aging (ofag270); POP-UP low-barrier care (ofag263); SARS-CoV-2 breakthrough & CD4 (ofag284); syphilis testing via VL monitoring, BC (ofag269); HCV micro-elimination barriers, SF (ofag285); bone/muscle in adolescents with HIV (ofag322); dapivirine ring vaginal microbiota (ofag329); inter-arm BP & CAD/PAD (ofag311); ML TIMP executive-phenotype predictors (ofag335); DTG pharmacovigilance Uganda (ofag252).

Viral Infections & Hepatitis

Systematic review / meta · OFID · abstract-only

hMPV vs RSV burden in adults with chronic illness

50 studies. RSV > hMPV positivity (inpatient OR 1.88) across most chronic conditions — but not in SOT recipients. Fellow takeaway: supports RSV vaccination priority; don't assume the two viruses behave identically (SOT signal).

PDF: comparison-of-human-metapneumovirus-and-respiratory-syncytial-virus.pdf

Case report / case series · OFID · abstract-only

Two neuroinvasive-virus alerts

H5N1 clade 2.3.2.1e CNS (pediatric): meningoencephalitis without respiratory symptoms; virus in CSF only. A negative respiratory panel doesn't exclude H5N1 — test CSF.
Powassan encephalitis delays (Vermont): POWV serology/CSF must be ordered specifically — add to the arboviral workup in tick-exposed NE/Great Lakes patients.

Also archived: severe WNV long-term sequelae (ofag295); RSV vs HRV acute-vs-chronic childhood burden (ofag314); HCV micro-elimination modeling in PWID (ofag297); HCV screening for former Soviet-bloc immigrants (ofag278); recurrent respiratory papillomatosis incidence, Denmark/Sweden (ofag290); arboviral/leptospiral immune-complex mechanism (ofag300).

Mycobacteria & TB

Real-world cohort · OFID · abstract-only

BPaL / BPaL-FQ for MDR-TB — California real-world

97 patients: favorable outcome 93%, no relapse — but 40% needed a drug change, mostly linezolid 600 mg/d toxicity. Fellow takeaway: BPaL(-FQ) works outside trials; linezolid toxicity is the dominant problem — anticipate dose reduction/TDM.

PDF: outcomes-and-treatment-limiting-adverse-events-of-patients.pdf

Systematic review / meta · OFID · abstract-only

Sensitivity of TB infection tests across populations

307 studies. T-SPOT.TB highest (88.2%); QFT 82.6%; TST ≥5 mm 80.3%. All drop substantially in people with HIV (QFT 66.5%). Fellow takeaway: in immunosuppressed/HIV, expect lower sensitivity and consider T-SPOT.TB; a negative test doesn't exclude infection.

PDF: sensitivity-of-tuberculosis-infection-diagnostic-tests-among-different.pdf

Also archived: nanopore sequencing for smear-negative TB (ofag323); cavitary-TB resistance by WGS+ML (ofag328); TB skin tests in healthcare workers, India (ofag268); DR-TB outcomes, South Kivu (ofag303); diabetes & hyperinflammation in melioidosis vs TB (ofag286).

Mycology

Case report / series · OFID · abstract-only

Two fungal teaching cases

Cryptococcal cellulitis, high CrAg: refractory "cellulitis" in an immunocompromised host with markedly elevated serum CrAg — a high serum CrAg mandates LP even without CNS findings.
Invasive fusariosis MIC series: triazole MICs ≥4 in 94%, yet 76% survived — high MICs don't preclude response; combination (triazole ± terbinafine) + source control reasonable.

Also archived: granulomatous amebic encephalitis — SR of 201 cases, mortality 76% (ofag289); invasive fungal sinusitis in hematologic malignancy, 20-yr (ofag304).

Transplant & Immunocompromised Host

Retrospective cohort · OFID · abstract-only

Infections during the CRS/ICANS phase after CAR-T

152 infusions; infection in 25.6% of CRS/ICANS episodes; fever/CRP lower at infection onset than at CRS/ICANS. 60-day infection 60% with multimodal immunosuppression vs 21% without (sHR 3.29). Fellow takeaway: during CRS/ICANS, fever/CRP are unreliable — low threshold for occult infection, especially after steroids + anti-IL-6.

PDF: infections-in-patients-with-cytokine-release-syndrome-immune.pdf

Also archived: molnupiravir-associated clearance of Cache Valley virus from CSF in an antibody-deficient child — salvage antiviral for untreatable RNA-virus CNS infection (ofag217); extended-criteria donor transplants & infection risk, SR (ofag187).

Vaccines & Prevention

Test-negative VE · OFID · abstract-only

Real-world RSVPreF3 effectiveness vs RSV hospitalization, ≥60

Overall VE 82.3% against lab-confirmed RSV-LRTD hospitalization, incl. higher-risk subgroups. Fellow takeaway: strong real-world confirmation supporting the ACIP recommendation to vaccinate high-risk adults ≥60.

PDF: real-world-effectiveness-of-adjuvanted-rsvpref3-vaccine-in.pdf

RCT (early/immunogenicity) · OFID · abstract-only

Three vaccine RCTs (immunobridging / pipeline)

Additional RZV dose 5–6 yrs out (ZOE-50/70): one extra dose gives a strong durable anamnestic response; basis for a possible future booster (not yet recommended).
C. difficile toxoid 2- vs 3-dose: overall non-inferiority NOT met (toxin B) — abbreviated schedule can't replace 3-dose; vaccine still investigational.
PRV-101 coxsackievirus B vaccine: phase 1, durable neutralizing Abs, no T1D/celiac autoimmunity signal — pipeline only.

Also archived: hybrid vs vaccine vs infection immunity to Omicron, K-Serosmart (ofag053); preexisting seasonal-coronavirus immunity boosts SARS-CoV-2 vaccine response (ofag232); salivary IgA/IgG after PPV23 (ofag273); influenza-uptake strategies in LMICs (ofag298); autovaccine immunotherapy for recurrent UTI (ofag315).

Diagnostics, Guidelines/Reviews & General ID

Also archived: calprotectin for LRTI/sepsis in the ED (ofag331); embolic-risk scores underperform in IE (ofag280); syndromic multiplex PCR yield in non-ventilator HAP (ofag272); RLDT rapid test for cholera (ofag292); chemiluminescence syphilis screening (ofag234); Borrelia/atypical CNS-infection review — verify organism in PDF (ofag333); embolic events in PWID with PFO & right-sided IE, SR (ofag245); digital labels in ID (viewpoint, ofag338); early ID-specialty exposure for undergrads (ofag255); first antimalarial efficacy study in Djibouti (ofag324).

One-time catch-up digest. Summaries are original paraphrases for educational use. Figures are taken from the archived full text; where the archived HTML was an abstract-only accepted manuscript, the primary-outcome figures were pulled from the archived publisher PDF (ACTIV-6, RSV+COVID co-administration, fosfomycin ESBL cUTI, Resist-3, S-337395, BioFire panel, HAP/VAP meta-analysis). Read the full articles at academic.oup.com/cid (subscription required). Citation: Clin Infect Dis 2026 (online ahead of print; cite by online date). PDFs for the high-yield set accompany this digest in the Drive folder. Anki: 10 cards minted this catch-up (FARTHEST, fosfomycin ESBL cUTI, STOP-Vanc, ACTIV-6, RSV+COVID co-administration, lenacapavir PrEP, HAP/VAP meta-analysis, BioFire panel, linezolid/MDR-TB, Resist-3 rabies); tagged CID::<Type> + Subject::Infectious_Disease. OFID section: open-access OFID backfill (92 articles archived, online Feb–Jun 2026; 23 featured); 18 OFID Anki cards minted, tagged OFID::<Type> + Subject::Infectious_Disease. OFID is open access (academic.oup.com/ofid + PMC); the full 92-article set is in the OFID Archive.